Janowsky_2005_Pharmacol.Biochem.Behav_81_917

Reference

Title : Anticholinesterase (DFP) toxicity antagonism by chronic donepezil: a potential nerve agent treatment - Janowsky_2005_Pharmacol.Biochem.Behav_81_917
Author(s) : Janowsky DS , Davis JM , Overstreet DH
Ref : Pharmacol Biochem Behav , 81 :917 , 2005
Abstract :

Animal studies exploring the antagonism of irreversible cholinesterase inhibitors (i.e. nerve agents) such as soman and sarin have shown that pretreatment with the reversible centrally acting cholinesterase inhibitor, physostigmine, alone or in conjunction with the centrally acting anticholinergic drug, scopolamine, antagonizes the lethality and toxicity of these agents. This study evaluated the effects of pretreatment with the oral cholinesterase inhibitor and anti-Alzheimer's agent, donepezil (Aricept) on the hypokinetic, hypothermic and diarrhea-inducing effects of the irreversible long-acting cholinesterase inhibitor, diisopropylfluorophosphate (DFP) in adult Sprague-Dawley rats. Donepezil (2 mg/kg), given acutely (30 min pretreatment) or chronically (10 daily treatments), significantly antagonized the hypothermia, hypoactivity and diarrhea induced by DFP (1.25 mg/kg) administration. The effects were most prominent 4 and 6 h after the injection of DFP and some protection was observed even when the last treatment of the chronic donepezil protocol was given 24 h before the DFP injection. Although these phenomena are not the same as lethality, they may be parallel phenomena, and our results may have therapeutic implications for the treatment of nerve agent toxicity.

PubMedSearch : Janowsky_2005_Pharmacol.Biochem.Behav_81_917
PubMedID: 16054679

Related information

Citations formats

Janowsky DS, Davis JM, Overstreet DH (2005)
Anticholinesterase (DFP) toxicity antagonism by chronic donepezil: a potential nerve agent treatment
Pharmacol Biochem Behav 81 :917

Janowsky DS, Davis JM, Overstreet DH (2005)
Pharmacol Biochem Behav 81 :917